文献速递类风湿关节炎

METTL14介导的TNFAIP3 m6A修饰参与活动性类风湿关节炎患者的炎症

METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients With Active Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2023-09-28

研究检测了活动性类风湿关节炎(RA)患者外周血单个核细胞(PBMCs)中m6A修饰水平及METTL14表达,发现METTL14与m6A水平降低且与DAS28负相关;敲低METTL14可促进IL-6和IL-17分泌及CAIA小鼠关节炎症,机制涉及m6A调控TNFAIP3 mRNA稳定性与转位。

要点

  • 活动性RA患者PBMCs中METTL14与m6A水平降低,且与DAS28负相关。
  • 敲低METTL14可上调IL-6和IL-17分泌,并加重CAIA小鼠关节炎症。
  • m6A通过调控TNFAIP3 mRNA稳定性与蛋白编码区转位影响其表达。

核心结论

  • m6A修饰在RA炎症进展调控中起关键作用,靶向m6A修饰的治疗策略可能成为RA管理的新选择。

研究设计与样本

  • 研究收集RA患者与健康对照的外周血单个核细胞(PBMCs),采用PCR、western blot和m6A ELISA检测m6A修饰相关蛋白表达及m6A水平。
  • 采用甲基化RNA免疫沉淀(MeRIP)测序和RNA免疫沉淀实验探索METTL14在RA炎症调控中的作用。
  • 以胶原抗体诱导关节炎(CAIA)小鼠作为体内模型研究METTL14在RA炎症进展中的作用。

主要发现

  • 活动性RA患者PBMCs中m6A写入蛋白METTL14及m6A水平降低,且与基于28关节计数的疾病活动度评分(DAS28)呈负相关。
  • 在RA患者PBMCs中敲低METTL14可下调m6A并促进炎性细胞因子白细胞介素6(IL-6)和IL-17分泌。
  • 在CAIA小鼠中敲低METTL14可促进关节炎症,伴IL-6和IL-17上调。
  • MeRIP测序和功能研究证实,核因子-κB炎症通路的关键抑制因子肿瘤坏死因子α诱导蛋白3(TNFAIP3)参与m6A调控的PBMCs过程。
  • 机制研究显示,m6A通过调控TNFAIP3信使RNA稳定性及TNFAIP3蛋白编码序列中的转位来影响TNFAIP3表达。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of the study was to investigate the role of N6 -methyladenosine (m6A) modification in the progression of rheumatoid arthritis (RA). METHODS: Peripheral blood mononuclear cells (PBMCs) from patients with RA and healthy controls were collected. The expression of m6A modification-related proteins and m6A levels were detected using polymerase chain reaction (PCR), western blot, and m6A enzyme-linked immunosorbent assay (ELISA). The roles of methyltransferase-like 14 (METTL14) in the regulation of inflammation in RA was explored using methylated RNA immunoprecipitation (MeRIP) sequencing and RNA immunoprecipitation assays. Collagen antibody-induced arthritis (CAIA) mice were used as an in vivo model to study the role of METTL14 in the inflammation progression of RA. RESULTS: We found that m6A writer METTL14 and m6A levels were decreased in PBMCs of patients with active RA and correlated negatively with the disease activity score using 28 joint counts (DAS28). Knockdown of METTL14 downregulated m6A and promoted the secretion of inflammatory cytokines interleukin 6 (IL-6) and IL-17 in PBMCs of patients with RA. Consistently, METTL14 knockdown promoted joint inflammation accompanied by upregulation of IL-6 and IL-17 in CAIA mice. MeRIP sequencing and functional studies confirmed that tumor necrosis factor α induced protein 3 (TNFAIP3), a key suppressor of the nuclear factor-κB inflammatory pathway, was involved in m6A-regulated PBMCs. Mechanistic investigations revealed that m6A affected TNFAIP3 expression by regulation of messenger RNA stability and translocation in TNFAIP3 protein coding sequence. CONCLUSIONS: Our study highlights the critical roles of m6A on regulation of inflammation in RA progression. Treatment strategies targeting m6A modification may represent a new option for management of RA.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Tang J, Yu Z, Xia J, et al. METTL14-Mediated m6A Modification of TNFAIP3 Involved in Inflammation in Patients With Active Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 37327357. doi:10.1002/art.42629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。